Marathon’s move on rare-disease drug puts phrma in a tight spot
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
WASHINGTON — The latest drug-pricing controversy is going to be more difficult for the industry’s Washington representatives to untangle themselves from. This time, the company in question
is a part of the club. PhRMA, the industry’s top lobbying group, has recently sought to distance its members from perceived bad actors like Turing and Valeant. Rolling out a new ad campaign
called “Go Boldly” last month, PhRMA president Stephen Ubl pledged that we would be seeing “less hoodie, more lab coats” from the industry. But now one of its members is testing that
playbook. Marathon Pharmaceuticals is taking heat after it received FDA approval for a drug that treats Duchenne muscular dystrophy, a devastating and fatal condition that afflicts children
— and then put an $89,000 per year (list) price tag on it. STAT+ Exclusive Story Already have an account? Log in THIS ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS
DAILY COVERAGE AND ANALYSIS OF THE PHARMA INDUSTRY — BY SUBSCRIBING TO STAT+. Already have an account? Log in Individual plans Group plans View All Plans To read the rest of this story
subscribe to STAT+. Subscribe